Literature DB >> 31776776

Current status of endovascular treatment for thoracoabdominal aortic aneurysms.

Takeshi Baba1, Takao Ohki2, Koji Maeda2.   

Abstract

Open surgical repair (OSR) for thoracoabdominal aortic aneurysms (TAAAs) is maximally invasive and associated with high rates of operative mortality and perioperative complications including spinal cord ischemia (SCI), despite improvements in surgical techniques and perioperative care. Elderly patients, patients with a history of aortic surgery, and patients with severe comorbidities are often considered ineligible for this surgery and endovascular treatment may be their only treatment option. Total endovascular aneurysm repair (t-EVAR) without debranching surgery does not require thoracotomy and laparotomy and could improve the outcomes of these patients. t-EVAR includes fenestrated EVAR (f-EVAR), multi-branched EVAR (b-EVAR), and physician-modified fenestration endograft (PMFG). Although these techniques have achieved lower mortality rates than OSR, there are concerns about perioperative complications including limb ischemia, SCI, and long-term outcomes such as endograft migration and endoleaks (ELs). This article provides an overview of available endovascular devices for TAAAs and reviews the short and mid-term results of t-EVAR, as well as alternative options.

Entities:  

Keywords:  Branched EVAR; Endoleak; Fenestrated EVAR; Spinal cord ischemia; Thoracoabdominal aortic aneurysms

Mesh:

Year:  2019        PMID: 31776776     DOI: 10.1007/s00595-019-01917-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  1 in total

1.  Proximal subtotal pancreatectomy as an alternative to total pancreatectomy for malnourished patients.

Authors:  Yuki Nakagawa; Hiroyuki Kato; Koki Maeda; Daisuke Noguchi; Kazuyuki Gyoten; Aoi Hayasaki; Yusuke Iizawa; Takehiro Fujii; Akihiro Tanemura; Yasuhiro Murata; Naohisa Kuriyama; Masashi Kishiwada; Hiroyuki Sakurai; Shuji Isaji; Shugo Mizuno
Journal:  Surg Today       Date:  2021-04-07       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.